- Report
- March 2025
- 120 Pages
Global
From €5390EUR$5,950USD£4,646GBP
- Report
- March 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- February 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- September 2024
- 253 Pages
Global
From €4077EUR$4,500USD£3,514GBP
- Report
- July 2025
- 200 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 194 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- August 2024
- 208 Pages
Global
From €2265EUR$2,500USD£1,952GBP
- Report
- April 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- March 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- March 2025
- 250 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- February 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- February 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- February 2025
- 200 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- January 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- July 2025
- 274 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 244 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 173 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 193 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 279 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 194 Pages
Global
From €5299EUR$5,850USD£4,568GBP

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more